As of November 10, 2026, Amneal Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: AMRX). The largest holder reporting an active stake on Schedule 13D is Tushar Patel, at 17.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Chintu Patel, the chief executive and a director (9.4%); Chirag K. Patel, the chief executive and president (8.4%) (Schedule 13D/A, August 12, 2026).
Is this your company?
About to sign with, pay or invest in Amneal Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Amneal Pharmaceuticals, Inc. a real, registered company?
- Amneal Pharmaceuticals, Inc. files with the SEC under CIK 1723128 (its SEC filings).
- Its shares are listed under the ticker AMRX on Nasdaq (SEC company record).
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Amneal Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Chintu Patel (filed 2026-08-12).
Who are Amneal Pharmaceuticals, Inc.'s owners and officers?
Amneal Pharmaceuticals, Inc.: industry Pharmaceutical Preparations (Schedule 13D/A, 2026-08-12).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-08-12 | Chintu Patel | 9.4% |
| Schedule 13D/A, 2026-08-12 | Chirag Patel | 8.4% |
| Schedule 13D/A, 2026-08-12 | Tushar Patel | 17.6% |
| Schedule 13G, 2026-04-27 | Blackrock, Inc. | 7.6% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13D/A, 2026-03-26 | Patel Dipan | 5.4% |
| Schedule 13D/A, 2025-10-07 | Patel Chintu | 8.2% |
| Schedule 13D/A, 2025-10-06 | Patel Dipan | 7.6% |
| Schedule 13D/A, 2025-08-08 | Patel Chirag K. | 7.1% |
Questions about who owns Amneal Pharmaceuticals, Inc.
Who owns Amneal Pharmaceuticals, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Amneal Pharmaceuticals, Inc.: Tushar Patel (17.6%, Schedule 13D/A, filed 2026-08-12), Chintu Patel (9.4%, Schedule 13D/A, filed 2026-08-12), Chirag Patel (8.4%, Schedule 13D/A, filed 2026-08-12), Patel Chintu (8.2%, Schedule 13D/A, filed 2025-10-07) and Blackrock, Inc. (7.6%, Schedule 13G, filed 2026-04-27); 2 more are listed above.
Who are the largest shareholders of Amneal Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Amneal Pharmaceuticals, Inc. on this page are Tushar Patel (17.6%), Chintu Patel (9.4%) and Chirag Patel (8.4%).
When did Tushar Patel buy into Amneal Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Tushar Patel on this page is the Schedule 13D/A, filed 2026-08-12, reporting 17.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Amneal Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Amneal Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Amneal Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Amneal Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 61,341,678 shares (17.6% of shares outstanding), held indirectly through By Limited Liability Companies Controlled by Family Trusts (Form 4, 2026-08-12).
- , the chief executive and a director: 32,523,507 shares (9.3% of shares outstanding), 1,388,521 held directly and 31,134,986 indirectly (Form 4, 2026-08-12).
- , the chief executive and president: 29,044,624 shares (8.3% of shares outstanding), 1,393,470 held directly and 27,651,154 indirectly (Form 4, 2026-08-12).
- , a director: 1,927,595 shares (0.55% of shares outstanding), 1,643,963 held directly and 283,632 indirectly (Form 4, 2026-08-12).
- , a director: 832,800 shares (0.24% of shares outstanding) (Form 4, 2026-05-08).
Shares outstanding: 348,412,726 as of 2026-10-30, from the company's latest SEC cover page.
How much has Amneal Pharmaceuticals, Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-08-10).
Keep reading
More on Amneal Pharmaceuticals, Inc. and the records around it.
Amneal Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
Companies that share a holder
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/amneal-pharmaceuticals